An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia

M. K. Kim, Jun Cheon, K. S. Lee, M. K. Chung, J. Y. Lee, S. W. Lee, S. W. Kim, B. H. Chung, K. Park, J. K. Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Patients and methods: In this multicentre, open-label and non-comparative study, a total of 135 sexually active patients with LUTS were enrolled in Korea to receive alfuzosin 10 mg once daily for 12 weeks. International Prostate Symptom Score (IPSS) and a 25-item MSHQ exploring erection ejaculation and satisfaction with sex life were evaluated at baseline after 4 and 12 weeks of treatment. Results: Of 135 patients (age 58.8 years, duration of LUTS 2.6 years, mean values), 110 (81.5%) completed the study. The ejaculatory domain of the MSHQ significantly improved at the end-point in the intent-to-treat population (score difference of 2.24, p ≤ 0.0001, n = 120). The domains of erection and sexual satisfaction improved at the end-point, but the score differences were not statistically significant. After the 12 weeks treatment, the total IPSS score significantly decreased from 17.9 to 12.1 (p < 0.0001), bother score decreased from 3.8 to 2.85 (p < 0.0001) and peak flow rate increased from 11.0 to 14.3 ml/s (p < 0.0001). A significant relationship between ejaculatory domains of MSHQ and IPSS was found. Four patients (2.9%) discontinued the trial for adverse event. Conclusions: Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction.

Original languageEnglish
Pages (from-to)345-350
Number of pages6
JournalInternational Journal of Clinical Practice
Volume64
Issue number3
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Reproductive Health
Multicenter Studies
Hyperplasia
Prostate
Lower Urinary Tract Symptoms
Orgasm
Ejaculation
Prostatic Hyperplasia
Korea
Surveys and Questionnaires
alfuzosin
Therapeutics
Quality of Life
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. / Kim, M. K.; Cheon, Jun; Lee, K. S.; Chung, M. K.; Lee, J. Y.; Lee, S. W.; Kim, S. W.; Chung, B. H.; Park, K.; Park, J. K.

In: International Journal of Clinical Practice, Vol. 64, No. 3, 01.02.2010, p. 345-350.

Research output: Contribution to journalArticle

Kim, M. K. ; Cheon, Jun ; Lee, K. S. ; Chung, M. K. ; Lee, J. Y. ; Lee, S. W. ; Kim, S. W. ; Chung, B. H. ; Park, K. ; Park, J. K. / An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. In: International Journal of Clinical Practice. 2010 ; Vol. 64, No. 3. pp. 345-350.
@article{6ef3d3a64df64cc5b6e32e0369eeb46f,
title = "An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia",
abstract = "Objectives: To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Patients and methods: In this multicentre, open-label and non-comparative study, a total of 135 sexually active patients with LUTS were enrolled in Korea to receive alfuzosin 10 mg once daily for 12 weeks. International Prostate Symptom Score (IPSS) and a 25-item MSHQ exploring erection ejaculation and satisfaction with sex life were evaluated at baseline after 4 and 12 weeks of treatment. Results: Of 135 patients (age 58.8 years, duration of LUTS 2.6 years, mean values), 110 (81.5{\%}) completed the study. The ejaculatory domain of the MSHQ significantly improved at the end-point in the intent-to-treat population (score difference of 2.24, p ≤ 0.0001, n = 120). The domains of erection and sexual satisfaction improved at the end-point, but the score differences were not statistically significant. After the 12 weeks treatment, the total IPSS score significantly decreased from 17.9 to 12.1 (p < 0.0001), bother score decreased from 3.8 to 2.85 (p < 0.0001) and peak flow rate increased from 11.0 to 14.3 ml/s (p < 0.0001). A significant relationship between ejaculatory domains of MSHQ and IPSS was found. Four patients (2.9{\%}) discontinued the trial for adverse event. Conclusions: Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction.",
author = "Kim, {M. K.} and Jun Cheon and Lee, {K. S.} and Chung, {M. K.} and Lee, {J. Y.} and Lee, {S. W.} and Kim, {S. W.} and Chung, {B. H.} and K. Park and Park, {J. K.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1111/j.1742-1241.2009.02247.x",
language = "English",
volume = "64",
pages = "345--350",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia

AU - Kim, M. K.

AU - Cheon, Jun

AU - Lee, K. S.

AU - Chung, M. K.

AU - Lee, J. Y.

AU - Lee, S. W.

AU - Kim, S. W.

AU - Chung, B. H.

AU - Park, K.

AU - Park, J. K.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objectives: To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Patients and methods: In this multicentre, open-label and non-comparative study, a total of 135 sexually active patients with LUTS were enrolled in Korea to receive alfuzosin 10 mg once daily for 12 weeks. International Prostate Symptom Score (IPSS) and a 25-item MSHQ exploring erection ejaculation and satisfaction with sex life were evaluated at baseline after 4 and 12 weeks of treatment. Results: Of 135 patients (age 58.8 years, duration of LUTS 2.6 years, mean values), 110 (81.5%) completed the study. The ejaculatory domain of the MSHQ significantly improved at the end-point in the intent-to-treat population (score difference of 2.24, p ≤ 0.0001, n = 120). The domains of erection and sexual satisfaction improved at the end-point, but the score differences were not statistically significant. After the 12 weeks treatment, the total IPSS score significantly decreased from 17.9 to 12.1 (p < 0.0001), bother score decreased from 3.8 to 2.85 (p < 0.0001) and peak flow rate increased from 11.0 to 14.3 ml/s (p < 0.0001). A significant relationship between ejaculatory domains of MSHQ and IPSS was found. Four patients (2.9%) discontinued the trial for adverse event. Conclusions: Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction.

AB - Objectives: To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Patients and methods: In this multicentre, open-label and non-comparative study, a total of 135 sexually active patients with LUTS were enrolled in Korea to receive alfuzosin 10 mg once daily for 12 weeks. International Prostate Symptom Score (IPSS) and a 25-item MSHQ exploring erection ejaculation and satisfaction with sex life were evaluated at baseline after 4 and 12 weeks of treatment. Results: Of 135 patients (age 58.8 years, duration of LUTS 2.6 years, mean values), 110 (81.5%) completed the study. The ejaculatory domain of the MSHQ significantly improved at the end-point in the intent-to-treat population (score difference of 2.24, p ≤ 0.0001, n = 120). The domains of erection and sexual satisfaction improved at the end-point, but the score differences were not statistically significant. After the 12 weeks treatment, the total IPSS score significantly decreased from 17.9 to 12.1 (p < 0.0001), bother score decreased from 3.8 to 2.85 (p < 0.0001) and peak flow rate increased from 11.0 to 14.3 ml/s (p < 0.0001). A significant relationship between ejaculatory domains of MSHQ and IPSS was found. Four patients (2.9%) discontinued the trial for adverse event. Conclusions: Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=74349096153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74349096153&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2009.02247.x

DO - 10.1111/j.1742-1241.2009.02247.x

M3 - Article

VL - 64

SP - 345

EP - 350

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 3

ER -